Finesse Solutions Forges Agreement With Leading Biotechnology Company for Single-Use Technology Exploration

Finesse Solutions Forges Agreement With Leading Biotechnology Company for Single-Use Technology Exploration

SAN JOSE, Calif., July 13 /PRNewswire/ -- Finesse Solutions, LLC, San Jose, CA, a manufacturer of measurement and control solutions for biologics applications today announced a development agreement with Biogen Idec, Inc. (Nasdaq: BIIB) aimed at evaluating emerging technologies for single-use bioprocessing. These technologies include novel disposable sensors, software platforms, and control algorithms.

As part of the agreement, Finesse will provide prototype sensors, software, and systems for use by Biogen Idec in its bioprocessing platforms, and refine them for single-use applications. This collaboration allows state-of-the art technologies to be honed in actual use-case scenarios, and will leverage the expertise of both companies.

Dr. Mark Selker, Chief Technology Officer and founder of Finesse, stated,"We are delighted to have the efforts of world-class scientists at Biogen Idec help refine our technologies and focus our development. This will go far in helping to optimize our products using actual cell culture platforms."

Dr. Thomas Ryll, Director Bioprocess Development at Biogen Idec, said, "We are excited about the opportunity to work with Finesse on testing and improving new sensor technology for use in our high productivity process platforms."


About Finesse Solutions, LLC

California-based Finesse Solutions, LLC, leads the way in developing new measurement and control technologies, in order to enable the transition to single-use systems, bring new capabilities to existing bioreactor platforms, and harmonize global bio-process information transfer. Our current product family provides comprehensive measurement and control solutions for upstream processes in the biotech and pharmaceutical industries. For more information, please visit us at www.finesse.com.

SOURCE Finesse Solutions, LLC

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.